Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
215.98
+8.15 (3.92%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,020 | 10,330 | 7,445 | 7,744 | 10,031 | 7,831 | |
Market Cap Growth | 70.29% | 38.75% | -3.86% | -22.80% | 28.09% | -14.84% |
Enterprise Value | 16,230 | 13,713 | 11,032 | 11,945 | 14,946 | 13,570 |
Last Close Price | 215.98 | 170.00 | 123.15 | 123.00 | 159.31 | 127.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.76 | - | 13.29 | 18.67 | - | - |
Forward PE | 12.94 | 7.67 | 5.72 | 6.29 | 8.54 | 8.23 |
PS Ratio | 3.05 | 2.42 | 1.83 | 2.02 | 2.74 | 2.53 |
PB Ratio | 2.91 | 2.39 | 1.82 | 2.07 | 3.25 | 1.98 |
P/FCF Ratio | 8.81 | 7.96 | 5.48 | 7.25 | 8.07 | 10.43 |
P/OCF Ratio | 8.44 | 7.62 | 5.33 | 7.09 | 7.89 | 10.06 |
PEG Ratio | 0.24 | 0.55 | 0.37 | 0.50 | 1.14 | 0.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.53 | 3.21 | 2.71 | 3.12 | 4.08 | 4.39 |
EV/EBITDA Ratio | 8.42 | 8.00 | 7.24 | 8.21 | 10.18 | 13.20 |
EV/EBIT Ratio | 13.42 | 13.47 | 12.77 | 14.63 | 17.81 | 28.55 |
EV/FCF Ratio | 10.20 | 10.57 | 8.13 | 11.18 | 12.03 | 18.07 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.92 | 1.26 | 1.51 | 1.55 | 1.89 | 1.56 |
Debt / EBITDA Ratio | 2.25 | 3.11 | 3.97 | 3.92 | 3.90 | 5.84 |
Debt / FCF Ratio | 2.77 | 4.18 | 4.54 | 5.43 | 4.68 | 8.22 |
Net Debt / Equity Ratio | 0.46 | 0.69 | 0.78 | 1.12 | 1.60 | 1.41 |
Net Debt / EBITDA Ratio | 1.15 | 1.74 | 2.08 | 2.87 | 3.36 | 5.43 |
Net Debt / FCF Ratio | 1.39 | 2.30 | 2.34 | 3.90 | 3.97 | 7.44 |
Asset Turnover | 0.42 | 0.36 | 0.35 | 0.35 | 0.32 | 0.33 |
Inventory Turnover | 0.84 | 0.79 | 0.58 | 0.43 | 0.30 | 0.37 |
Quick Ratio | 1.38 | 1.46 | 3.57 | 1.52 | 1.64 | 1.43 |
Current Ratio | 1.78 | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 |
Return on Equity (ROE) | 22.11% | -8.47% | 14.31% | 12.16% | -6.35% | -8.65% |
Return on Assets (ROA) | 6.86% | 5.38% | 4.61% | 4.59% | 4.53% | 3.15% |
Return on Invested Capital (ROIC) | 17.17% | 13.97% | 11.39% | 10.25% | 9.55% | 7.13% |
Return on Capital Employed (ROCE) | 13.70% | 10.80% | 7.90% | 8.30% | 8.50% | 4.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.78% | -3.45% | 7.52% | 5.36% | -2.23% | -4.21% |
FCF Yield | 11.35% | 12.56% | 18.24% | 13.79% | 12.39% | 9.59% |
Buyback Yield / Dilution | -5.40% | 7.61% | 8.41% | -15.23% | -4.77% | -5.62% |